Journal of Stem Cell Research & Therapy

Oncolytic Virus Therapy of Triple Negative-ER negative, PR-negative, HER-2-negative Metastatic Breast Cancer and Patients Safety and Efficacy

7^th International Conference on Stem Cell, Tissue Engineering and Regenerative Medicine

February 27-28, 2025 | Paris, France

Ashok Srivastava

Rutgers University Business Management, USA

Scientific Tracks Abstracts: J Stem Cell Res Ther

Abstract:

Breast cancer is the most common cancer in women worldwide. It is also the principle cause of death from cancer among women globally. Despite the high incidence rates, in Western countries, 89% of women diagnosed with breast cancer are still alive 5 years after their diagnosis, which is due to detection and treatment. Breast cancer incidence has been increasing. In 2015, an estimated 231,840 new cases of invasive breast cancer are expected to be diagnosed in women in the U.S., along with 60,290 new cases of non-invasive (in situ) breast cancer. About 2,350 new cases of invasive breast cancer are expected to be diagnosed in men in 2022. A manâ??s lifetime risk of breast cancer is about 1 in 1,000. Breast cancer incidence rates in the U.S. began decreasing after increasing for the previous two decades. They dropped by 7% from 2015 to 2020 alone. One theory is that this decrease was partially due to the reduced use of hormone replacement therapy (HRT) by women after the results of a large study called the Womenâ??s Health Initiative were published. These results suggested a connection between HRT and increased breast cancer risk. About 40,290 women in the U.S. are expected to die in 2023 from breast cancer, though death rates have been decreasing since 1989. Women under 50 have experienced larger decreases. These decreases are thought to be the result of treatment advances, earlier detection through screening, and increased awareness. All drugs for breast cancer treatment developed and in market cause mild to several side effects, and safety issue, however, risk manage ment of breast cancer drugs are difficult to report and manage. A series of challenges of breast cancer therapy and the drug safety will be reported and discussed.

Biography :

Dr. Ashok Srivastava is Chief Medical Officer Trans Atlantic Therapeutics Oncology, He was Chief Medical Officer of CareBe yond - A Radiation Therapy Cancer Center, New Jersey, USA. He has more than 15 years of experience in drug development , medical affairs and commercialization of cancer drugs including radiopharmaceutical and supportive care; Phase I – 4, and marketing commercialization of Hematology, Oncology and radio pharmacetuical drugs in USA , EU and Japan. He is leader in Cancer Drug Development Worldwide large and complex Phase 3 Clinical Trials in many countries. He contributed to 21 INDs and 7-NDAs of Cancer Drugs, acquisition /merger of company and drug for more than $300 million. He received his clinical, medical training & worked at renowned medical centers and pharmaceutical institutions worldwide; Walter Reed Army Institute of Research and Medical Center, Daiichi, Sumitomo, Pharmacia, Pfizer, Eisai Oncology, and Spectrum Pharma ceuticals.